Related Experiment Video
Updated: Jun 11, 2025
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
A bibliometric analysis of research on PD-1/PD-L1 in urinary tract tumors
Yongming Chen1, Xiaojin Lu2, Genyuan Peng3
1Beijing Hospital National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Abstract:
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are key components in immune checkpoint studies across various tumors, including those in the urinary tract. The utilization of PD-1/PD-L1 inhibitors in urinary tract tumors is on the rise. This study provides a comprehensive overview of PD-1/PD-L1 research in urinary tract tumors through bibliometric analysis. A search was conducted in the Web of Science Core Collection (WoSCC) database for academic papers on PD-1/PD-L1 in urinary tract tumors published between January 1, 1999, and September 3, 2022. Tools such as VOSviewer, CiteSpace, and an online bibliometric platform, were used for an in-depth analysis covering countries, institutions, authors, journals, references, and keywords. A total of 1,711 articles on PD-1/PD-L1 in urinary tract tumors were analyzed. The United States led in article contributions, followed by China and Japan. Harvard University was the top institution in this research area. With notable conctributions from Choueiri TK, who authored 48 related articles. The Journal for Immunotherapy of Cancer was the top publisher, and Topalian SL's 2012 publication in The New England Journal of Medicine was the most cited article. Key author keywords included "immunotherapy," "PD-L1," "renal cell carcinoma," "bladder cancer," and "immune checkpoint inhibitors." Notably, research on the role of PD-1/PD-L1 in kidney and bladder cancer has garnered significant attention.
Insights
This bibliometric analysis reviews research on Programmed cell death 1 (PD-1) and its ligand PD-L1 in urinary tract cancers. The United States leads global contributions in this growing field of cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Bibliometrics
Background:
- Programmed cell death 1 (PD-1) and its ligand PD-L1 are critical in immune checkpoint regulation.
- Immune checkpoint inhibitors targeting PD-1/PD-L1 are increasingly used for urinary tract tumors.
- Understanding research trends in this area is vital for advancing cancer therapy.
Purpose of the Study:
- To conduct a bibliometric analysis of PD-1/PD-L1 research in urinary tract tumors.
- To identify key countries, institutions, authors, and publications in this field.
- To map the intellectual structure and research hotspots of PD-1/PD-L1 in urinary tract cancers.
Main Methods:
- Bibliometric analysis using Web of Science Core Collection (1999-2022).
- Analysis of 1,711 articles on PD-1/PD-L1 in urinary tract tumors.
- Utilized VOSviewer, CiteSpace, and an online platform for data visualization and analysis.
Main Results:
- The United States, China, and Japan are leading countries in PD-1/PD-L1 research for urinary tract tumors.
- Harvard University and author TK Choueiri are prominent contributors.
- The Journal for Immunotherapy of Cancer and a 2012 NEJM publication by SL Topalian are highly influential.
Conclusions:
- Research on PD-1/PD-L1 in urinary tract tumors, particularly kidney and bladder cancer, is rapidly expanding.
- Bibliometric analysis highlights key players and trends, informing future research directions in cancer immunotherapy.
- The study provides a comprehensive overview of the global research landscape for PD-1/PD-L1 in urologic oncology.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
